The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Open accessAbstract
Introduction Retrospective studies have shown immune-related adverse events (irAEs) to be associated with better prognosis. However, no prospective clinical trials have been conducted, and little is known regarding the association between irAEs and the outcome of patients with NSCLC after treatment with immunotherapy.Methods We conducted a prospective cohort study of patients with advanced NSCLC who were treated with nivolumab between January and December 2016. The association between clinical outcome and irAEs 2 to 6 weeks after commencement of nivolumab treatment was investigated. IrAEs were assessed by at least three independent medical professionals.Results A total of 43 patients were enrolled, including 19 patients with irAEs 2 weeks after commencement of nivolumab treatment. Common irAEs included rash, pyrexia, and diarrhea. Programmed cell death ligand 1-positive tumor cell expression was not significantly different between patients with and without irAEs. The objective response and disease control rates were higher in patients with irAEs than in those without irAEs (37% versus 17% and 74% versus 29% [p = 0.17 and p < 0.01], respectively]). Patients with irAEs were associated with a significantly longer median progression-free survival than those without (6.4 months [95% confidence interval: 2.5-not reached] versus 1.5 months [95% confidence interval: 1.2-2.3] [p = 0.01]). These findings were comparable to those for patients with and without irAEs 6 weeks after commencement of nivolumab treatment.Conclusions Early irAEs are associated with a better outcome after treatment with immunotherapy. We predicted responses to nivolumab by using early irAEs. Further research is needed to elucidate the mechanisms of these associations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both ORR and DCR were higher in patients who experienced IRAEs at ≤2 weeks and ≤ 6 weeks compared to those who did not experience them.”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.5.584 · Cited by 3,991
Postmus, P. E., Brambilla, E. M., Chansky, K., Crowley, J. J., Goldstraw, P. G., Patz, E. F., & Yokomise, H. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31811f4703 · Cited by 1,593
Flagged first, then by citations
Cited by
Sorted by citations
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L., Barroso‐Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 550
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Bai, R., Lv, Z., Xu, D., & Cui, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00209-0 · Cited by 486
Cortellini, A., Bersanelli, M., Buti, S., Cannita, K., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Michiara, M., Di Marino, P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0527-y · Cited by 413
Hussaini, S. M. Q., Chehade, R., Boldt, G., Raphael, J., Blanchette, P., Vareki, S. M., & Fernandes, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102134 · Cited by 412
Berner, F., Bomze, D., Diem, S., Ali, O. H., Fässler, M., Ring, S., Niederer, R., Ackermann, C. J., Baumgaertner, P., Pikor, N., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0402 · Cited by 395
Xia, L., Liu, Y., & Wang, Y. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-io-s1-s05 · Cited by 397
Sato, K., Akamatsu, H., Murakami, E., Sasaki, S., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Koh, Y., Ueda, H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.019 · Cited by 377
Ricciuti, B., Genova, C., De Giglio, A., Bassanelli, M., Dal Bello, M. G., Metro, G., Brambilla, M., Baglivo, S., Grossi, F., & Chiari, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2805-3 · Cited by 345
Rogado, J., Sánchez-Torres, J. M., Romero-Laorden, N., Ballesteros, A. I., Pacheco-Barcia, V., Ramos-Leví, A., Arranz, R., Lorenzo, A., Gullón, P., Donnay, O., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.014 · Cited by 255
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Braaten, T. J., Brahmer, J. R., Forde, P. M., Le, D., Lipson, E. J., Naidoo, J., Schollenberger, M., Zheng, L., Bingham, C. O., Shah, A. A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216109 · Cited by 230
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Zhao, B., Zhao, H., & Zhao, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937612 · Cited by 213
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Passaro, A., Leighl, N. B., Blackhall, F. H., Popat, S., Kerr, K. M., Ahn, M., Arcila, M. E., Arrieta, O. G., Planchard, D., de Marinis, F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.003 · Cited by 209
Grangeon, M., Tomasini, P., Chaleat, S., Jeanson, A., Souquet-Bressand, M., Khobta, N., Bermudez, J., Trigui, Y., Greillier, L., Blanchon, M., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.10.002 · Cited by 205
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Nishio, M., Mok, T. S. K., Reck, M., Finley, G. G., Kaul, M. D., Yu, W., Paranthaman, N., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.7711 · Cited by 191
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
Nakamura, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00119 · Cited by 185
Cortellini, A., Chiari, R., Ricciuti, B., Metro, G., Perrone, F., Tiseo, M., Bersanelli, M., Bordi, P., Santini, D., Giusti, R., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.02.006 · Cited by 181
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
Eun, Y., Kim, I. Y., Sun, J., Lee, J., Cha, H., Koh, E.-M., Kim, H., & Lee, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50574-6 · Cited by 178
Cook, S., Samuel, V., Meyers, D. E., Stukalin, I., Litt, I., Sangha, R. S., Morris, D. G., Heng, D. Y. C., Pabani, A., Dean, M. L., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.52302 · Cited by 182
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
To, K. K. W., Fong, W., & Cho, W. C. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635007 · Cited by 157
Fujimoto, D., Yoshioka, H., Kataoka, Y., Morimoto, T., Kim, Y. H., Tomii, K., Ishida, T., Hirabayashi, M., Hara, S., Ishitoko, M., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.02.017 · Cited by 147
Self-citationOwen, D. H., Wei, L., Bertino, E. M., Edd, T., Villalona-Calero, M. A., He, K., Shields, P. G., Carbone, D. P., & Otterson, G. A. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.08.008 · Cited by 146
Combination therapy with PD-1 or PD-L1 inhibitors for cancer
Hayashi, H., & Nakagawa, K. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01548-1 · Cited by 144
Masuda, K., Shoji, H., Nagashima, K., Yamamoto, S., Ishikawa, M., Imazeki, H., Aoki, M., Miyamoto, T., Hirano, H., Honma, Y., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6150-y · Cited by 143
on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group, Verzoni, E., Cartenì, G., Cortesi, E., Giannarelli, D., De Giglio, A., Sabbatini, R., Buti, S., Rossetti, S., Cognetti, F., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0579-z · Cited by 140
Wang, M., Zhai, X., Li, J., Guan, J., Xu, S., Li, Y., & Zhu, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670391 · Cited by 143
Clinical assessment of immune-related adverse events
Sosa, A. E., Cadena, E. L., Olivé, C. S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918764628 · Cited by 137
Duma, N., Abdel-Ghani, A., Yadav, S., Hoversten, K. P., Reed, C. T., Sitek, A. N., Enninga, E. A. L., Paludo, J., Aguilera, J. V., Leventakos, K., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0094 · Cited by 136
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Aredo, J. V., Mambetsariev, I., Hellyer, J. A., Amini, A., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., Cabebe, E. C., Naidoo, J., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1628 · Cited by 134
Petrelli, F., Grizzi, G., Ghidini, M., Ghidini, A., Ratti, M., Panni, S., Cabiddu, M., Ghilardi, M., Borgonovo, K., Parati, M. C., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000300 · Cited by 129
Harnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125
Fan, Y., Xie, W., Huang, H., Wang, Y., Li, G., Geng, Y., Hao, Y., & Zhang, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633032 · Cited by 125
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Lim, S. M., Hong, M. H., & Kim, H. R. (2020) · Immune Network · doi:10.4110/in.2020.20.e10 · Cited by 123
Fukihara, J., Sakamoto, K., Koyama, J., Ito, T., Iwano, S., Morise, M., Ogawa, M., Kondoh, Y., Kimura, T., Hashimoto, N., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.07.006 · Cited by 114
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy
Jing, Y., Zhang, Y., Wang, J., Li, K., Chen, X., Heng, J., Gao, Q., Ye, Y., Zhang, Z., Liu, Y., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab035 · Cited by 103
Raschi, E., Mazzarella, A., Antonazzo, I. C., Bendinelli, N., Forcesi, E., Tuccori, M., Moretti, U., Poluzzi, E., & De Ponti, F. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00632-w · Cited by 101
Greally, M., Chou, J. F., Chatila, W. K., Margolis, M. L., Capanu, M., Hechtman, J. F., Tuvy, Y., Kundra, R., Daian, F., Ladanyi, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3603 · Cited by 103
Takada, K., Shimokawa, M., Takamori, S., Shimamatsu, S., Hirai, F., Tagawa, T., Okamoto, T., Hamatake, M., Tsuchiya‐Kawano, Y., Otsubo, K., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33557 · Cited by 100
Vitale, E., Rizzo, A., Maistrello, L., Güven, D. C., Massafra, R., Mollica, V., Monteiro, F. S. M., Santoni, M., & Massari, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-71746-z · Cited by 104
Suzuki, Y., Karayama, M., Uto, T., Fujii, M., Matsui, T., Asada, K., Kusagaya, H., Kato, M., Matsuda, H., Matsuura, S., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.04.002 · Cited by 98
Okada, N., Kawazoe, H., Takechi, K., Matsudate, Y., Utsunomiya, R., Zamami, Y., Goda, M., Imanishi, M., Chuma, M., Hidaka, N., et al. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.004 · Cited by 96
Ahn, B., Pyo, K., Xin, C.-F., Jung, D., Shim, H. S., Lee, C. Y., Park, S. Y., Yoon, H. I., Hong, M. H., Cho, B. C., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02899-y · Cited by 95
Matsuo, M., Yasumatsu, R., Masuda, M., Toh, S., Wakasaki, T., Hashimoto, K., Taura, M., Uchi, R., & Nakagawa, T. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104525 · Cited by 92
Basak, E. A., van der Meer, J. W. M., Hurkmans, D. P., Schreurs, M. W. J., Hoop, E. O., van der Veldt, A. A. M., Bins, S., Joosse, A., Koolen, S. L. W., Debets, R., et al. (2020) · Thyroid · doi:10.1089/thy.2019.0726 · Cited by 92
Afzal, M. Z., Dragnev, K. H., Sarwar, T., & Shirai, K. (2019) · Lung Cancer Management · doi:10.2217/lmt-2018-0016 · Cited by 90
Ksienski, D., Wai, E. S., Croteau, N. S., Fiorino, L., Brooks, E., Poonja, Z., Fenton, D., Geller, G., Glick, D., & Lesperance, M. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.09.005 · Cited by 86
Cortellini, A., Friedlaender, A., Banna, G. L., Porzio, G., Bersanelli, M., Cappuzzo, F., Aerts, J. G. J. V., Giusti, R., Bria, E., Cortinovis, D. L., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.06.010 · Cited by 86
Sato, R., Imamura, K., Sakata, S., Ikeda, T., Horio, Y., Iyama, S., Akaike, K., Hamada, S., Jodai, T., Nakashima, K., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060762 · Cited by 88
Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors
Zhong, L., Wu, Q., Chen, F., Liu, J., & Xie, X. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02803-5 · Cited by 87
Foster, C. C., Couey, M., Kochanny, S. E., Khattri, A., Acharya, R. K., Tan, Y. C., Brisson, R. J., Leidner, R. S., & Seiwert, T. Y. (2021) · Cancer · doi:10.1002/cncr.33780 · Cited by 83
Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review
Collins, M., Soularue, É., Marthey, L., & Carbonnel, F. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.033 · Cited by 83
Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
Kalfeist, L., Galland, L., Ledys, F., Ghiringhelli, F., Limagne, E., & Ladoire, S. (2022) · Cells · doi:10.3390/cells11050770 · Cited by 78
Akamatsu, H., Murakami, E., Oyanagi, J., Shibaki, R., Kaki, T., Takase, E., Tanaka, M., Harutani, Y., Yamagata, N., Okuda, Y., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0299 · Cited by 78
Self-citationSekine, K., Kanda, S., Goto, Y., Horinouchi, H., Fujiwara, Y., Yamamoto, N., Motoi, N., & Ohe, Y. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.08.012 · Cited by 78
Ozawa, Y., Amano, Y., Kanata, K., Hirotsugu, H., Matsui, T., Kakutani, T., Koyauchi, T., Tanahashi, M., Niwa, H., Yokomura, K., et al. (2019) · Medical Oncology · doi:10.1007/s12032-019-1255-3 · Cited by 73
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
Raimondi, A., Sepe, P., Zattarin, E., Mennitto, A., Stellato, M., Claps, M., Guadalupi, V., Verzoni, E., de Braud, F., & Procopio, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01644 · Cited by 76
Anderson, R., Theron, A. J., & Rapoport, B. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02254 · Cited by 73
Takada, K., Takamori, S., Yoneshima, Y., Tanaka, K., Okamoto, I., Shimokawa, M., Oba, T., Osoegawa, A., Tagawa, T., Takenoyama, M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.034 · Cited by 72
Honjo, O., Kubo, T., Sugaya, F., Nishizaka, T., Kato, K., Hirohashi, Y., Takahashi, H., & Torigoe, T. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0582-4 · Cited by 71
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
Yang, F., Shay, C., Abousaud, M. I., Tang, C., Li, Y., Qin, Z. S., Saba, N. F., & Teng, Y. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02568-y · Cited by 76
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 71
Yang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 73
Remón, J., Mezquita, L., Corral, J., Vilariño, N., & Reguart, N. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.52 · Cited by 68
Oyanagi, J., Koh, Y., Sato, K., Mori, K. P., Teraoka, S., Akamatsu, H., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.020 · Cited by 66
Self-citationCortellini, A., Buti, S., Agostinelli, V., & Bersanelli, M. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.10.003 · Cited by 62
Wang, D., Chen, C., Gu, Y., Lu, W., Zhan, P., Liu, H., Lv, T., Song, Y., & Zhang, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.631949 · Cited by 62
Mangan, B. L., McAlister, R. K., Balko, J. M., Johnson, D. B., Moslehi, J. J., Gibson, A., & Phillips, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14433 · Cited by 62
Xu, S., Lai, R., Zhao, Q., Zhao, P., Zhao, R., & Guo, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.794099 · Cited by 59
Kim, K. H., Hur, J. Y., Cho, J., Ku, B. M., Koh, J., Koh, J., Sun, J., Lee, S., Ahn, J. S., Park, K., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1722023 · Cited by 60
Aso, M., Toi, Y., Sugisaka, J., Aiba, T., Kawana, S., Saito, R., Ogasawara, T., Tsurumi, K., Ono, K., Shimizu, H., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0550 · Cited by 57
Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors
Gault, A., Anderson, A. E., Plummer, R., Stewart, C. J., Pratt, A. G., & Rajan, N. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19750 · Cited by 56
Takamori, S., Takada, K., Shimokawa, M., Matsubara, T., Fujishita, T., Ito, K., Toyozawa, R., Yamaguchi, M., Okamoto, T., Yoneshima, Y., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.026 · Cited by 55
Takada, K., Toyokawa, G., Yoneshima, Y., Tanaka, K., Okamoto, I., Shimokawa, M., Wakasu, S., Haro, A., Osoegawa, A., Tagawa, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50079-2 · Cited by 55
Riudavets, M., Mosquera, J., García‐Campelo, R., Serra-López, J., Anguera, G., Gallardo, P., Sullivan, I., Joaquín, A. B., del Carpio, L. P., Barnadas, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01677 · Cited by 55
Wang, W., Gu, X., Wang, L., Pu, X., Feng, H., Xu, C., Lou, G., Shao, L., Xu, Y., Wang, Q., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03115-y · Cited by 54
Abu‐Sbeih, H., Tang, T., Ali, F. S., Johnson, D. H., Qiao, W., Diab, A. K., & Wang, Y. (2018) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_12_18 · Cited by 53
Takada, K., Yoneshima, Y., Tanaka, K., Okamoto, I., Shimokawa, M., Wakasu, S., Takamori, S., Toyokawa, G., Oba, T., Osoegawa, A., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03146-5 · Cited by 53
Zhao, Z., Wang, X., Qu, J., Zuo, W., Tang, Y., Zhu, H., & Chen, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708195 · Cited by 49
Okamoto, I., Sato, H., Kondo, T., Koyama, N., Fushimi, C., Okada, T., Miura, K., Matsuki, T., Yamashita, T., Omura, G., et al. (2019) · Acta Oto-Laryngologica · doi:10.1080/00016489.2019.1648867 · Cited by 50
Sugano, T., Seike, M., Saito, Y., Kashiwada, T., Terasaki, Y., Takano, N., Hisakane, K., Takahashi, S., Tanaka, T., Takeuchi, S., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13364 · Cited by 50
Park, R., Lopes, L., & Saeed, A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02397-5 · Cited by 50
Bjørnhart, B., Hansen, K. H., Jørgensen, T. L., Herrstedt, J., & Schytte, T. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1615636 · Cited by 49
Dóra, D., Bokhari, S. M. Z., Aloss, K., Takacs, P., Desnoix, J. Z., Szklenárik, G., Hurley, P. D., & Lohinai, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032769 · Cited by 48
de Coaña, Y. P., Wolodarski, M., Àvila, I. V. D. H., Nakajima, T., Rentouli, S., Lundqvist, A., Masucci, G. V., Hansson, J., & Kiessling, R. W. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1786888 · Cited by 48
Dupont, R., Bérard, E., Puisset, F., Comont, T., Delord, J., Guimbaud, R., Meyer, N., Mazières, J., & Alric, L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1682383 · Cited by 47
Treatment of immune checkpoint inhibitor-induced inflammatory arthritis
Jeurling, S., & Cappelli, L. C. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000701 · Cited by 47
Li, L., Liu, Y., Chen, C., Wei, A., & Li, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190001 · Cited by 45
Murray, J. C., Sivapalan, L., Hummelink, K., Balan, A., White, J. R., Niknafs, N., Rhymee, L., Pereira, G., Rao, N., Weksler, B., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1469 · Cited by 47
The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors
Fukushima, T., Kobayashi, S., & Ueno, M. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae067 · Cited by 48
Remón, J., Vilariño, N., & Reguart, N. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.002 · Cited by 45
Ksienski, D., Wai, E. S., Croteau, N. S., Freeman, A. T., Chan, A. M. Y., Fiorino, L., Brooks, E. G., Poonja, Z., Fenton, D. W., Geller, G. S., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.005 · Cited by 45
Berti, A., Bortolotti, R., Dipasquale, M., Kinspergher, S., Prokop, L. J., Grandi, G., Inchiostro, S., Paolazzi, G., Caffo, O., & Veccia, A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103351 · Cited by 49
Okawa, S., Kayatani, H., Fujiwara, K., Ozeki, T., Takada, K., Iwamoto, Y., Minami, D., Sato, K., & Shibayama, T. (2019) · Internal Medicine · doi:10.2169/internalmedicine.1001-18 · Cited by 44
Hirashima, T., Kanai, T., Suzuki, H., Yoshida, H., MATSUSHITA, A., KAWASUMI, H., Samejima, Y., Noda, Y., Nasu, S., Tanaka, A., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13832 · Cited by 44
Suzuki, K., Yanagihara, T., Matsumoto, K., Kusaba, H., Yamauchi, T., Ikematsu, Y., Tanaka, K., Otsubo, K., Inoue, H., Yoneshima, Y., et al. (2020) · International Immunology · doi:10.1093/intimm/dxaa022 · Cited by 46
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 43
Hosoya, K., Fujimoto, D., Morimoto, T., Kumagai, T., Tamiya, A., Taniguchi, Y., Yokoyama, T., Ishida, T., Hirano, K., Matsumoto, H., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.01.003 · Cited by 43
Self-citationThuillier, P., Joly, C., Alavi, Z., Crouzeix, G., Descourt, R., Quéré, G., Kerlan, V., & Roudaut, N. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02802-6 · Cited by 44
Das, S., Ciombor, K. K., Haraldsdottir, S., Pumpalova, Y., Sahin, I. H., Pineda, G., Shyr, Y., Lin, E. P., Hsu, C.-Y., Chu, S.-K., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0637 · Cited by 41
Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?
Putzu, C., Canova, S., Paliogiannis, P., Lobrano, R., Sala, L., Cortinovis, D. L., & Colonese, F. (2023) · Cancers · doi:10.3390/cancers15030689 · Cited by 42
Metadata
- Authors
- Teraoka, S., Fujimoto, D., Morimoto, T., Kawachi, H., Ito, M., Sato, Y., Nagata, K., Nakagawa, A., Otsuka, K., Uehara, K., Imai, Y., Ishida, K., Fukuoka, J., & Tomii, K.
- Affiliations
- Kobe City Medical Center General Hospital (JP)
- Hyogo Medical University (JP)
- Nagasaki University Hospital (JP)
- Corresponding author
- Fujimoto, Daichi
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 12
- Issue
- 12
- Pages
- 1798-1805
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2754877046
- Cited by
- 375
- References
- 26
- Citations by year
- 2026: 10 · 2025: 25 · 2024: 29 · 2023: 29 · 2022: 44 · 2021: 68 · 2020: 79 · 2019: 67 · 2018: 22 · 2017: 2
- FWCI
- 20.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- immune-related adverse events, nivolumab, non-small cell lung cancer, immune checkpoint inhibitors, immunotherapy response prediction, progression-free survival, PD-L1 expression, rash, fever, diarrhea, objective response rate
- MeSH terms
- Nivolumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Middle Aged, Prospective Studies, Cohort Studies, Treatment Outcome, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
